# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-042952
Filing Date
2024-04-09
Accepted
2024-04-09 16:01:51
Documents
75
Period of Report
2024-02-29

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | neog-20240229.htm iXBRL | 10-Q | 2323378
2 | EX-31.1 | neog-ex31_1.htm | EX-31.1 | 13766
3 | EX-31.2 | neog-ex31_2.htm | EX-31.2 | 13581
4 | EX-32 | neog-ex32.htm | EX-32 | 11110
| Complete submission text file | 0000950170-24-042952.txt |  | 10214605

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | neog-20240229.xsd | EX-101.SCH | 1646326
79 | EXTRACTED XBRL INSTANCE DOCUMENT | neog-20240229_htm.xml | XML | 1860312

Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 10-Q | Act: 34 | File No.: 000-17988 | Film No.: 24832675
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)